TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05034471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-Chord™ Device Technologies
Description: Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
Study: NCT06121362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protocatechuic Acid or PCA
Description: PCA 1000 mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06302998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX-PRESSIN
Description: This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
Study: NCT06194032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Participants will receive baxdrostat as two separate doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Participants will receive baxdrostat as two separate doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Participants will receive baxdrostat as two separate doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Participants will receive baxdrostat as two separate doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive baxdrostat matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive baxdrostat matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive baxdrostat matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive baxdrostat matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single dose moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single dose moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single dose moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single dose moxifloxacin
Study: NCT05887895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection、INS068 injection、HR20014 injection
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.
Study: NCT05466006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation with subepithelial connective tissue graft (SCTG)
Description: After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)
Description: After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
Study: NCT04791475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.
Description: The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.
Description: The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
Study: NCT05213143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
Study: NCT06204211

Intervention type: DIAGNOSTIC_TEST
Intervention: ophthalmologic examinations
Description: All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.

Intervention type: DIAGNOSTIC_TEST
Intervention: ophthalmologic examinations
Description: All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
Study: NCT06270667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise
Description: Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
Study: NCT05473104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills
Description: Social training targeting adolescents with ASD and focused on making and keeping friends
Study: NCT06123390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Responses to Illness Severity Quantification (RISQ) System
Description: The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
Study: NCT04670198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Empowerment Skills
Description: The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-list control
Description: Usual care for 6 months, followed by the YES programme.
Study: NCT05875363

Intervention type: OTHER
Intervention: collect data
Description: The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure.

Intervention type: OTHER
Intervention: collect data
Description: The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure.

Intervention type: OTHER
Intervention: collect data
Description: The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure.
Study: NCT04380623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone-Based Web-Page: HPV vaccine
Description: Website to be accessed via mobile phone to deliver tailored educational material
Study: NCT05451186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye patch and headphones
Description: Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
Study: NCT04380623

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Phone-Based Web-Page: HPV vaccine
Description: Website to be accessed via mobile phone to deliver tailored educational material
Study: NCT05367193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy for vitreoretinal disease in highly myopic eyes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
Study: NCT05363449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103 Cream
Description: UHE-103 is an investigational combinational therapy containing keratolytic and antifungal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin (naftifine hydrochloride) Cream
Description: Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
Study: NCT05367193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGENUITY® 3D Visualization System (Alcon, TX, USA)
Description: Injection of ICG to stain internal limiting membrane
Study: NCT01078792

Intervention type: OTHER
Intervention: CT pulmonary angio, blood tests
Study: NCT05390918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAILOR
Description: The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
Study: NCT06014918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A new smart device application (Smart APS)
Description: The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
Study: NCT05042115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education in pain neurosciences and clinical hypnosis
Description: Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment
Description: Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
Study: NCT06504914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
Study: NCT05496530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal triamcinolone acetonide injection
Description: Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal triamcinolone acetonide injection
Description: Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal triamcinolone acetonide injection
Description: Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
Study: NCT04637230

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram analysis by Artificial Intelligence
Description: 1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram analysis by Artificial Intelligence
Description: 1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram analysis by Artificial Intelligence
Description: 1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram analysis by Artificial Intelligence
Description: 1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
Study: NCT05595850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Online non-meditation mindfulness program
Study: NCT04637230

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram analysis by Artificial Intelligence
Description: 1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
Study: NCT05406557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial pulpotomy
Description: In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Miniature pulpotomy
Description: In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
Study: NCT05595850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Learning
Description: Online learning program
Study: NCT04858438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insufflation during surgery
Description: This is the amount of insufflation using during the surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insufflation during surgery
Description: This is the amount of insufflation using during the surgical procedure.
Study: NCT04861779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK29116
Description: Oral HSK29116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK29116
Description: Oral HSK29116